News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026
London, June 2, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on Thursday, June 4, 2026, at 9:55 EDT/ 14:55 BST.
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments.
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
London, March 19, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments.
Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
LONDON and REDWOOD CITY, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the appointment of Richard Francis as Head of Pharmaceutical Development , effective August 1.
Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif. , June 13, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
LONDON , May 03, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH, NASDAQ:MREO), a clinical stage, UK -based, biopharmaceutical company focused on rare diseases, today announces that the Trustee of the Mereo BioPharma Group plc Employee Benefit Trust (the “Trust”), Link Trustees
Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON , April 26, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK -based, biopharmaceutical company focused on rare diseases, today announced that it will release preliminary
Mereo BioPharma Group today announces that, in connection with the completed merger with OncoMed Pharmaceuticals, Inc.
Mereo BioPharma Group today announces that, in connection with the completed merger with OncoMed Pharmaceuticals, Inc.
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc.
Mereo BioPharma Group plc announces that the merger with OncoMed Pharmaceuticals, Inc. ("OncoMed" NASDAQ:OMED) announced on 5 December 2018 has today completed.
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting
LONDON, April 18, 2019 -- Mereo BioPharma Group plc, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement dated 5 December 2018 between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo (the "Merger"), at a meeting of OncoMed's stockholders duly convened and held on 17 April 2019.
Mereo Publicly Files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
Mereo BioPharma Group plc a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that a further step towards the proposed combination (the "Proposed Transaction") with OncoMed Pharmaceuticals, Inc. ("OncoMed") has been taken, with the filing by Mereo of its preliminary registration statement on Form F-4 (the "Form F-4") with the U.S. Securities and Exchange Commission (the "SEC").
Mereo Biopharma Announces Positive Results From The Safety Extension Study To The Phase 2b Clinical Trial Of Bgs-649 For The Treatment Of Hypogonadotropic Hypogonadism In Obese Men
Mereo BioPharma : first patient dosed in phase 2 alpha-1 antitrypsin deficiency study
Mereo announces positive top-line results from Phase 2 trial with BCT-197 (acumapimod)
Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announces positive top-line data from a Phase 2 clinical trial with BCT-197 (acumapimod), a novel, orally active p38 MAP kinase inhibitor in development as a first-line therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
